Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, ...

The US president has given manufacturers as little as one year to relocate production back to the US or face 200% tariffs.

The pressure comes on top of a project to cut medicine prices in the United States to align them with the lowest rates elsewhere.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

“I don’t claim to know everything or have all the answers,” notes Belén Garijo, CEO of German giant Merck Group. But the company of 62,000 people in life science, health care, and tech always plans ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Chief executive Belén Garijo on Monday called the deal a "major step" for Merck, adding that it will sharpen the company’s focus on patients with rare tumours, accelerate company growth, and ...

Merck’s chief executive officer and executive board chair, Belén Garijo, described the acquisition as a “major step in [the company’s] active portfolio strategy”. “For our healthcare sector, it ...

0650 ET – Merck KGaA anticipates its research and development costs will normalize to industry-peer levels as its pipeline advances and recent deals mature, Chief Executive Officer Belen Garijo ...